These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10822307)

  • 1. High efficiency retroviral vectors that contain no viral coding sequences.
    Yu SS; Kim JM; Kim S
    Gene Ther; 2000 May; 7(9):797-804. PubMed ID: 10822307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
    Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
    Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of retroviral vectors with enhanced efficiency of transgene expression.
    Hahm SH; Yi Y; Lee DK; Noh MJ; Yun L; Hwang S; Lee KH
    J Virol Methods; 2004 Nov; 121(2):127-36. PubMed ID: 15381349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering the splice acceptor for improved gene expression and viral titer in an MLV-based retroviral vector.
    Lee JT; Yu SS; Han E; Kim S; Kim S
    Gene Ther; 2004 Jan; 11(1):94-9. PubMed ID: 14681702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine leukemia virus derived retroviral vector with a rat VL30 packaging psi sequence.
    Torrent C; Wang P; Darlix JL
    Bone Marrow Transplant; 1992; 9 Suppl 1():143-7. PubMed ID: 1324044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors.
    Zhao Y; Low W; Collins MK
    Gene Ther; 2000 Feb; 7(4):300-5. PubMed ID: 10694810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.
    Byun J; Kim SH; Kim JM; Yu SS; Robbins PD; Yim J; Kim S
    Gene Ther; 1996 Sep; 3(9):780-8. PubMed ID: 8875226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
    Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors.
    Miskin J; Chipchase D; Rohll J; Beard G; Wardell T; Angell D; Roehl H; Jolly D; Kingsman S; Mitrophanous K
    Gene Ther; 2006 Feb; 13(3):196-205. PubMed ID: 16208418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MuLV packaging systems as models for estimating/measuring retrovirus recombination frequency.
    Patience C; Takeuch Y; Cosset FL; Weiss RA
    Dev Biol (Basel); 2001; 106():169-79; discussion 253-63. PubMed ID: 11761229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of retroviral vectors to cotransfer human endogenous retroviruses (HERVs) from human packaging cell lines.
    Zeilfelder U; Frank O; Sparacio S; Schön U; Bosch V; Seifarth W; Leib-Mösch C
    Gene; 2007 Apr; 390(1-2):175-9. PubMed ID: 17045761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
    J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General principles of retrovirus vector design.
    Chang T; Yee JK
    Methods Enzymol; 2012; 507():1-14. PubMed ID: 22365766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
    Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
    J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved retroviral packaging lines derived from spleen necrosis virus.
    Martinez I; Dornburg R
    Virology; 1995 Apr; 208(1):234-41. PubMed ID: 11831705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the gag region on genome stability: avian retroviral vectors that contain sequences from the Bryan strain of Rous sarcoma virus.
    Federspiel MJ; Hughes SH
    Virology; 1994 Sep; 203(2):211-20. PubMed ID: 8053145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poxviral/retroviral chimeric vectors allow cytoplasmic production of transducing defective retroviral particles.
    Holzer GW; Mayrhofer JA; Gritschenberger W; Dorner F; Falkner FG
    Virology; 1999 Jan; 253(1):107-14. PubMed ID: 9887323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
    Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
    Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.